Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

This process includes comprehensive molecular simulations of the ion channel in its native membrane environment, depicting its open, closed, and inactivated states, and ensemble virtual screening that accounts for conformational mobility in each state. Tentative binding pockets are investigated inside the pore, at the gating region, and in allosteric sites to cover the full spectrum of possible mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O60840

UPID:
CAC1F_HUMAN

ALTERNATIVE NAMES:
Voltage-gated calcium channel subunit alpha Cav1.4

ALTERNATIVE UPACC:
O60840; A6NI29; F5CIQ9; O43901; O95226; Q9UHB1

BACKGROUND:
Voltage-gated calcium channel subunit alpha Cav1.4 is integral to calcium ion entry in excitable cells, influencing muscle contraction, neurotransmitter release, and cell motility. Its unique property of activating at more hyperpolarized voltages and exhibiting robust calcium-dependent inactivation makes it a key player in calcium signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Voltage-dependent L-type calcium channel subunit alpha-1F could open doors to potential therapeutic strategies. Its involvement in critical retinal diseases underscores the importance of Cav1.4 as a target for developing treatments aimed at preserving or restoring vision.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.